Lipid Metabolism and Statin Therapy in Neurodegenerative Diseases: An Endocrine View.
Creators
- 1. Section of Endocrinology, Endocrinology Diabetology and Andrology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Sergio Pansini 5, 80138 Naples, Italy.
- 2. University of Naples Federico II
- 3. UNESCO Chair "Education for Health and Sustainable Development", University of Naples Federico II, 80138 Naples, Italy.
Description
Background/aim: A growing body of evidence suggests a link between dyslipidemias and neurodegenerative diseases, highlighting the crucial role of lipid metabolism in the health of the central nervous system. The aim of our work was to provide an update on this topic, with a focus on clinical practice from an endocrinological point of view. Endocrinologists, being experts in the management of dyslipidemias, can play a key role in the prevention and treatment of neurodegenerative conditions, through precocious and effective lipid profile optimization. Methods: The literature was scanned to identify clinical trials and correlation studies on the association between dyslipidemia, statin therapy, and the following neurodegenerative diseases: Alzheimer's disease (AD), Parkisons's disease (PD), Multiple sclerosis (MS), and Amyotrophic lateral sclerosis (ALS). Results: Impaired lipid homeostasis, such as that frequently observed in patients affected by obesity and diabetes, is related to neurodegenerative diseases, such as AD, PD, and other cognitive deficits related to aging. AD and related dementias are now a real priority health problem. In the United States, there are approximately 7 million subjects aged 65 and older living with AD and related dementias, and this number is projected to grow to 12 million in the coming decades. Lipid-lowering therapy with statins is an effective strategy in reducing serum low-density lipoprotein cholesterol to normal range concentrations and, therefore, cardiovascular disease risk; moreover, statins have been reported to have a positive effect on neurodegenerative diseases. Conclusions: Several pieces of research have found inconsistent information following our review. There was no association between statin use and ALS incidence. More positive evidence has emerged regarding statin use and AD/PD. However, further large-scale prospective randomized control trials are required to properly understand this issue.
Open Access
Licence Attribution (CC BY)
Publisher Website
Access full text
Publication Details
Journal article
Persistent Identifiers
References
Pappolla . Mild hypercholesterolemia is an early risk factor for the development...
Read more
Bandres-Ciga, S., Diez-Fairen, M., Kim, J.J., and Singleton, A.B. (2020). Geneti...
Read more
Refolo . Hypercholesterolemia accelerates the Alzheimer\u2019s amyloid pathology...
Read more
Bateman . Dominantly Inherited Alzheimer Network Clinical biomarker changes in d...
Read more
Sawcer . A whole genome screen for linkage disequilibrium in multiple sclerosis ...
Read more
Showing first 5 of 206 references.
Scholarly Citations
Cited by other scholarly works
013-344-762-306-69X
Read more
Showing first 1 of 1 scholarly citations.